|Articles|October 16, 2019
Treatment of Plaque Psoriasis
On August 1 2019, the U.S. Food and Drug Administration (FDA) expanded the approved indication for Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064%, for the topical treatment of plaque psoriasis to include patients age 12 and older. The decision is supported, in part, by the Enstilar Pediatric Study (NCT02387853) in adolescents age 12 to 17 with psoriasis of the body and scalp.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Content
Latest CME
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
4
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
5
